Diabetes is Curable, Part Seven
Orthodox medical treatment
After the diagnosis of diabetes, modern orthodox medical treatment consists of either oral hypoglycemic agents or insulin.
In 1955, oral hypoglycemic drugs were introduced. Currently available oral hypoglycemic agents fall into five classifications according to their biophysical mode of action.
These classes are:
Biguanides
Glucosidase inhibitors
Meglitinides
Sulfonylureas
Thiazolidinediones
The biguanides lower blood sugar in three ways. They inhibit the normal release, by the liver, of its glucose stores, they interfere with intestinal absorption of glucose from ingested carbohydrates and they are said to increase peripheral uptake of glucose.
The glucosidase inhibitors are designed to inhibit the amylase enzymes produced by our pancreas and which are essential to the digestion of carbohydrates. The theory is that if the digestion of carbohydrates is inhibited the blood sugar cannot be elevated.
The meglitinides are designed to stimulate the pancreas to produce insulin in a patient that likely already has an elevated level of insulin in their bloodstream. Only rarely does the doctor even measure insulin levels. This drug is frequently prescribed without any knowledge of pre-existing insulin levels. The fact that elevated insulin levels are almost as damaging as elevated glucose levels is widely ignored.
The sulfonylureas are another pancreatic stimulant class designed to stimulate the production of insulin. Serum insulin determinations are rarely made by the doctor before prescribing this drug. This drug is often prescribed for type II diabetics, many of whom already have elevated ineffective insulin. These drugs are notorious for causing hypoglycemia as a side effect.
The thiazolidinediones are famous for causing liver cancer. One of them, Rezulin, was approved in the USA through devious political infighting but failed to get approval in England because it was known to cause liver cancer. The first doctor that had responsibility to approve it at the FDA refused to do so. It was only after he was replaced by a more compliant official that Rezulin gained approval by the FDA. It went on to kill well over 100 diabetes patients and cripple many others before the fight to get it off the market was finally won. Rezulin was designed to stimulate the uptake of glucose from the bloodstream by the peripheral cells and to inhibit the normal secretion of glucose by the liver. The politics of why this drug ever came to market and then remained in the market for such an unexplainable length of time with regulatory agency approval is not clear.
Today insulin is prescribed for both the Type I and Type II diabetics. Injectable insulin substitutes for the insulin that the body no longer produces. Of course, this treatment, while necessary to preserving life for the Type I diabetic, is highly questionable when applied to the Type II diabetic.
It is important to note that neither insulin nor any of these oral hypoglycemic agents exert any curative action whatsoever on any type of diabetes. None of these medical strategies are designed to normalize the cellular uptake of glucose by the cells that need it to power their activity.
The prognosis with this orthodox treatment is increasing disability and early death from heart or kidney failure or the failure of some other vital organ.
The third step to a cure for this disease is to become informed and to apply an alternative methodology that is soundly based upon good science.
Leave a Reply